Sanofi wins big in battle for nano-drug maker

January 29, 2018
Sanofi announced a second major acquisition this month that will boost its work in treating blood disorders.

France's Sanofi announced Monday that it had reached a deal to acquire Belgian biotech firm Ablynx that values the firm at 3.9 billion euros ($4.8 billion), beating out Danish rival Novo Nordisk for the nano-drug maker.

Novo Nordisk earlier this month made a 2.6-billion-euro offer to buy the firm that is developing nano-drugs to treat blood disorders, which Ablynx rejected as too little.

Chief executive Olivier Brandicourt said by acquiring Ablynx that Sanofi will be expanding its portfolio of drugs that are close to market and "strengthening our platform for growth in rare blood disorders."

Ablynx specialises in the development of nanobodies: small fragments of antibodies that like larger antibodies can bind onto the antigens that cause an .

One of its nanobodies furthest along in development, caplacizumab, aims to treat a certain type of blood clot.

Ablynx's Edwin Moses said "we believe Sanofi's global infrastructure, commitment to innovation and commercial capabilities will accelerate our ability to deliver our pipeline" of products under development to the market.

Sanofi said that while it expected the addition of Ablynx would increase the long-term value of the company to shareholders by adding to its pipeline of drugs under development, research expenses would mean no increased earnings per share this year or in 2019.

The purchase of Ablynx is the second major acquisition by Sanofi this month, after announcing last week it would buy US biotech company Bioverativ, which specialises in treatments for haemophilia and rare blood disorders, for $11.6 billion (9.4 billion euros).

Sanofi's shares dipped 0.2 percent in a Paris market up slightly overall.

Explore further: Novo Nordisk woos Belgian nano-drug maker

Related Stories

Novo Nordisk woos Belgian nano-drug maker

January 8, 2018
Denmark's Novo Nordisk, the world's leading insulin manufacturer, announced Monday an offer to buy the Belgian biotech firm Ablynx for 2.6 billion euros ($3.1 billion).

Sanofi buys US haemophilia treatment firm for $11.6 bn (Update)

January 22, 2018
French pharmaceutical firm Sanofi said Monday it had reached an agreement to purchase US biotech company Bioverativ, which specialises in treatments for haemophilia and rare blood disorders, for $11.6 billion.

Belgium's Ablynx in Merck cancer research tie-up: firm

February 3, 2014
Belgian biotechnology company Ablynx said on Monday it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros ($2.3 billion).

Sanofi profits hit by falling US sales of diabetes drugs

November 2, 2017
French pharmaceutical giant Sanofi on Thursday posted a drop in third-quarter earnings, hit by a decline in sales of its diabetes drugs in the United States.

French pharma giant Sanofi says profits up in 2016

February 8, 2017
French pharmaceuticals giant Sanofi said Wednesday that cost-cutting measures and the strong performance of its rare diseases business drove up profits last year.

French drug giant Sanofi vows hostile bid for US prey (Update)

April 29, 2016
French pharmaceutical giant Sanofi vowed to open a hostile takeover battle Friday after its $9.3 billion (8.2 million-euro) offer for US cancer drug maker Medivation was dismissed for being too cheap.

Recommended for you

Drug overdose epidemic goes far beyond opioids, requires new policies

November 7, 2018
Most government-funded initiatives to address the overdose epidemic in the United States have targeted opioids specifically and have neglected other drugs that are increasingly implicated in overdoses, such as cocaine and ...

Zebrafish larvae help in search for appetite suppressants

November 2, 2018
Researchers at the University of Zurich and Harvard University have developed a new strategy in the search for psychoactive drugs. By analyzing the behavior of larval zebrafish, they can filter out substances with unwanted ...

FDA OKs powerful opioid pill as alternative to IV painkiller

November 2, 2018
U.S. regulators on Friday approved a fast-acting, super-potent opioid tablet as an alternative to IV painkillers used in hospitals.

Amphetamine-related hospitalizations surged between 2003 and 2015

November 2, 2018
An analysis conducted by Hennepin Healthcare, University of Minnesota School of Public Health and University of Michigan researchers shows amphetamine-related hospitalizations increased more than 270 percent from 2008 to ...

Cocaine-fentanyl overdoses underscore need for more 'test strips' and rapid response

November 1, 2018
Penn Medicine emergency department physicians are calling for more readily available testing strips to identify the presence of fentanyl in patients experiencing a drug overdose, and a rapid, coordinated response among health ...

Combination drug targeting opioid system may help relieve symptoms of major depression

October 29, 2018
Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment. The results of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.